518 related articles for article (PubMed ID: 28367239)
1. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
Zheng Z; Jin X; Lin B; Su H; Chen H; Fei S; Zhao L; Deng X; Xie D; Xie C
J Cancer; 2017; 8(4):597-605. PubMed ID: 28367239
[No Abstract] [Full Text] [Related]
2. Treatment outcome comparisons between exons 19 and 21 EGFR mutations for non-small-cell lung cancer patients with malignant pleural effusion after first-line and second-line tyrosine kinase inhibitors.
Zheng Z; Xie D; Su H; Lin B; Zhao L; Deng X; Chen H; Fei S; Jin X; Xie C
Tumour Biol; 2017 Jun; 39(6):1010428317706211. PubMed ID: 28618947
[TBL] [Abstract][Full Text] [Related]
3. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of clinical outcomes of patients with non-small cell lung cancer harboring different types of epidermal growth factor receptor sensitive mutations after first-line EGFR-TKI treatment].
Liu JJ; Zhang S; Wu CJ; Ma LX; Liu Y; Li H; Cui HX; Cheng Y
Zhonghua Zhong Liu Za Zhi; 2016 Mar; 38(3):211-7. PubMed ID: 26988828
[TBL] [Abstract][Full Text] [Related]
5. Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study.
Kim TH; Choi JH; Ahn MS; Lee HW; Kang SY; Choi YW; Koh YW; Sheen SS
BMC Cancer; 2024 Jan; 24(1):70. PubMed ID: 38216948
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of EGFR 19-del and 21-L858R mutations in patients with non-small cell lung cancer.
Hong W; Wu Q; Zhang J; Zhou Y
Oncol Lett; 2019 Oct; 18(4):3887-3895. PubMed ID: 31516600
[TBL] [Abstract][Full Text] [Related]
8. Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.
Rossi S; Toschi L; Finocchiaro G; Di Noia V; Bonomi M; Cerchiaro E; Ceresoli GL; Beretta GD; D'Argento E; Santoro A
Clin Lung Cancer; 2019 Mar; 20(2):82-87. PubMed ID: 30473385
[TBL] [Abstract][Full Text] [Related]
9. Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.
Zhang Y; Sheng J; Kang S; Fang W; Yan Y; Hu Z; Hong S; Wu X; Qin T; Liang W; Zhang L
PLoS One; 2014; 9(9):e107161. PubMed ID: 25222496
[TBL] [Abstract][Full Text] [Related]
10. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
Sheng M; Wang F; Zhao Y; Li S; Wang X; Shou T; Luo Y; Tang W
Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356
[TBL] [Abstract][Full Text] [Related]
11. EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients.
Choi YW; Jeon SY; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Koh YW; Han JH; Sheen SS
Am J Clin Oncol; 2018 Apr; 41(4):385-390. PubMed ID: 26967328
[TBL] [Abstract][Full Text] [Related]
12. Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone.
Wang Y; Wu G; Li R; Luo Y; Huang X; He L; Zhong H; Xiong S
Front Public Health; 2021; 9():677862. PubMed ID: 34222178
[No Abstract] [Full Text] [Related]
13. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
14. Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer.
Li H; Zhang X; Cao J; Su P; Lian J; Song X; Yang W; Han S; Xi Y; Wang Y
Tumour Biol; 2015 Dec; 36(12):9251-8. PubMed ID: 26091796
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of EGFR-Tyrosine Kinase Inhibitors for advanced non-small cell lung cancer patients harboring rare EGFR mutations of exon 18 E709X.
Hao Y; Xu M; Zhou H; Si J; Fang Y; Xu C; Song Z
Med Oncol; 2022 Dec; 40(1):34. PubMed ID: 36460861
[TBL] [Abstract][Full Text] [Related]
16. Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer.
Jiang H; Zhu M; Li Y; Li Q
Mol Clin Oncol; 2019 Sep; 11(3):301-308. PubMed ID: 31384460
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Won YW; Han JY; Lee GK; Park SY; Lim KY; Yoon KA; Yun T; Kim HT; Lee JS
J Clin Pathol; 2011 Nov; 64(11):947-52. PubMed ID: 21725039
[TBL] [Abstract][Full Text] [Related]
18. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
Arriola E; García Gómez R; Diz P; Majem M; Martínez Aguillo M; Valdivia J; Paredes A; Sánchez-Torres JM; Peralta Muñoz S; Barneto I; Gutierrez V; Andrade Santiago JM; Aparisi F; Isla D; Ponce S; Vicente Baz D; Artal A; Amador M; Provencio M
BMC Cancer; 2018 Jan; 18(1):106. PubMed ID: 29382302
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
20. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.
Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Bria E; Spitaleri G; Rossi A; Novello S
Lung Cancer; 2016 May; 95():73-81. PubMed ID: 27040855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]